SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer.

about

Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma.Enterohepatic recirculation model of irinotecan (CPT-11) and metabolite pharmacokinetics in patients with glioma.Unresolved issues in the management of endometrial cancer.

P2860

Q37159547-41358D32-4CA3-4B2D-BF2F-AC75D0DF4AE8 Q37558026-9207DC35-7E07-4763-A480-3C99C6EBBE5F Q37821897-2A028F47-3397-4888-900D-F50DF1BD1CA8

P2860

SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer.

Item

http://www.wikidata.org/entity/Q36613525

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

SCOTROC 2B: feasibility of car ...... ne therapy for ovarian cancer.

@ast

SCOTROC 2B: feasibility of car ...... ne therapy for ovarian cancer.

@en

type

Item

label

SCOTROC 2B: feasibility of car ...... ne therapy for ovarian cancer.

@ast

SCOTROC 2B: feasibility of car ...... ne therapy for ovarian cancer.

@en

prefLabel

SCOTROC 2B: feasibility of car ...... ne therapy for ovarian cancer.

@ast

SCOTROC 2B: feasibility of car ...... ne therapy for ovarian cancer.

@en

P1476

SCOTROC 2B: feasibility of car ...... ne therapy for ovarian cancer.

@en

P2093

A Hindley

http://www.w3.org/2001/XMLSchema#string

A R Clamp

http://www.w3.org/2001/XMLSchema#string

B Sorbe

http://www.w3.org/2001/XMLSchema#string

D Cruickshank

http://www.w3.org/2001/XMLSchema#string

G C Jayson

http://www.w3.org/2001/XMLSchema#string

J Ledermann

http://www.w3.org/2001/XMLSchema#string

J Mäenpää

http://www.w3.org/2001/XMLSchema#string

P M Wilkinson

http://www.w3.org/2001/XMLSchema#string

P Vasey

http://www.w3.org/2001/XMLSchema#string

R Welch

http://www.w3.org/2001/XMLSchema#string

P2860

Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000

Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer.

Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study.

The addition of topotecan to carboplatin and paclitaxel as first-line therapy for advanced ovarian cancer; is it possible only with peripheral blood stem cell support?

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.

Phase 2 trial of carboplatin, paclitaxel, and irinotecan in ovarian, fallopian tube, and primary peritoneal cancers.

Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study.

Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial.

Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial.

P2888

sj.bjc.6602910

P304

55-61

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6602910

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2006-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7368340

http://www.w3.org/2001/XMLSchema#string

P6179

1040026833

http://www.w3.org/2001/XMLSchema#string

P698

16404360

http://www.w3.org/2001/XMLSchema#string

P921

ovarian cancer

P932

2361090

http://www.w3.org/2001/XMLSchema#string

SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer.

about

P2860

P2860

SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P577

P5875

P6179

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P577

P5875

P6179

P698

P921

P932